Description

Attention should be paid to available information on bacterial resistance to ciprofloxacin before initiating treatment. Consideration should be given to official guidance on the appropriate use of antibacterial agents. In adults Lower respiratory tract infections due to Gram-negative bacteria * exacerbations of chronic obstructive pulmonary disease * bronchopulmonary infections in cystic fibrosis or bronchiectasis Chronic purulent otitis media Acute exacerbations of chronic sinusitis, particularly due to Gram-negative bacteria Urinary tract infections Genital tract infections * gonococcal urethritis and cervicitis due to susceptible strains of Neisseria gonorrhoeae * epididymo-orchitis, including infections due to susceptible strains of Neisseria gonorrhoeae * Upper gynaecological infections including infections due to susceptible strains of Neisseria gonorrhoeae. · Gastrointestinal infections (e.g. travellers’ diarrhoea) · Intra-abdominal infections · Skin and soft tissue infections due to Gram-negative bacteria · Malignant otitis externa · Osteoarticular infections · Prophylaxis of invasive Neisseria meningitidis infections · Anthrax (post-exposure prophylaxis and curative treatment) Ciprofloxacin may be used for the treatment of febrile neutropenic patients suspected of bacterial origin. In children and adolescents · Bronchopulmonary infections in cystic fibrosis due to Pseudomonas aeruginosa · Complicated urinary tract infections and pyelonephritis · Anthrax (post-exposure prophylaxis and curative treatment) Ciprofloxacin may also be used to treat severe infections in children and adolescents, if necessary. Treatment should only be initiated by physicians experienced in the treatment of cystic fibrosis and/or severe infections in children and adolescents.